New research shows positive experiences may boost the brain’s energy transformation, possibly building resilience against brain disorders in later life.
People with a history of cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia after age 70.
Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
A newly discovered function for the ApoE4 gene, the strongest genetic risk factor for Alzheimer’s disease, may help explain how the gene causes cognitive decline.
A new anti-inflammatory drug may offer hope for people with a progressive form of MS. In a phase 2 trial, the drug slowed brain atrophy in people with the disease.
A Mailman study of more than 1 million pregnancies in Finland reports that prenatal exposure to elevated levels of DDT is associated with an increased risk for autism.
A new clinical trial suggests that donepezil does not improve cognitive performance in people with mild cognitive impairment who also have clinical depression.
In one of the first studies of its kind, Columbia’s Philip De Jager shows how "big data" analyses may lead to new treatment strategies for Alzheimer's disease.
Scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.